Bumetanide continuous infusions in critically ill pediatric patients

Katie M. McCallister, Rebecca F. Chhim, Mario Briceno-Medina, Chasity Shelton, Mayte Figueroa, Mark Rayburn

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVE: Limited data exist for the use of bumetanide continuous infusions in children. The purpose of this study was to evaluate the use of bumetanide continuous infusions in critically ill pediatric patients. DESIGN: This study was an institutional review board approved, single-center, retrospective chart review of 95 patients. Dosing practices were described by rate (μg/kg/hr), duration (days), and previous diuretic use. Efficacy, determined by ability to achieve negative fluid balance and time to reach negative fluid balance, was assessed at 12, 24, and 48 hours. Safety was evaluated based on prevalence of adverse drug reactions. Adverse drug reactions were predefined as serum potassium concentration less than 3 mEq/L, serum chloride concentration less than 90 mEq/L, serum carbon dioxide concentration greater than 35 mEq/L, and serum creatinine increased greater than 1.5 times baseline and above patient-specific normal range. SETTING: Le Bonheur Children's Hospital, Memphis, TN. PATIENTS: Critically ill patients who are 18 years old or younger and received bumetanide continuous infusions. A total of 95 patients were included. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The mean dose of bumetanide was 5.7 ± 2.2 μg/kg/hr (1-10 μg/kg/hr) with a median duration of 3.3 days (0.3-18.5). The total percentage of patients achieving negative fluid balance by 48 hours was 76% with 54% of patients reaching negative fluid balance within 12 hours. CONCLUSIONS: This study showed that a bumetanide dose of 5.7 μg/kg/hr was effective in achieving negative fluid balance in the majority of critically ill pediatric patients. Additionally, bumetanide appears to be a safe loop diuretic for use as a continuous infusion at the doses described in critically ill pediatric patients.

Original languageEnglish (US)
Pages (from-to)e19-e22
JournalPediatric Critical Care Medicine
Volume16
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Bumetanide
Critical Illness
Pediatrics
Water-Electrolyte Balance
Drug-Related Side Effects and Adverse Reactions
Serum
Sodium Potassium Chloride Symporter Inhibitors
Research Ethics Committees
Diuretics
Carbon Dioxide
Chlorides
Creatinine
Potassium
Reference Values
Safety

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Critical Care and Intensive Care Medicine

Cite this

McCallister, K. M., Chhim, R. F., Briceno-Medina, M., Shelton, C., Figueroa, M., & Rayburn, M. (2015). Bumetanide continuous infusions in critically ill pediatric patients. Pediatric Critical Care Medicine, 16(2), e19-e22. https://doi.org/10.1097/PCC.0000000000000303

Bumetanide continuous infusions in critically ill pediatric patients. / McCallister, Katie M.; Chhim, Rebecca F.; Briceno-Medina, Mario; Shelton, Chasity; Figueroa, Mayte; Rayburn, Mark.

In: Pediatric Critical Care Medicine, Vol. 16, No. 2, 01.01.2015, p. e19-e22.

Research output: Contribution to journalArticle

McCallister, KM, Chhim, RF, Briceno-Medina, M, Shelton, C, Figueroa, M & Rayburn, M 2015, 'Bumetanide continuous infusions in critically ill pediatric patients', Pediatric Critical Care Medicine, vol. 16, no. 2, pp. e19-e22. https://doi.org/10.1097/PCC.0000000000000303
McCallister, Katie M. ; Chhim, Rebecca F. ; Briceno-Medina, Mario ; Shelton, Chasity ; Figueroa, Mayte ; Rayburn, Mark. / Bumetanide continuous infusions in critically ill pediatric patients. In: Pediatric Critical Care Medicine. 2015 ; Vol. 16, No. 2. pp. e19-e22.
@article{ec6a9283e1814c19a421a4f50f663675,
title = "Bumetanide continuous infusions in critically ill pediatric patients",
abstract = "OBJECTIVE: Limited data exist for the use of bumetanide continuous infusions in children. The purpose of this study was to evaluate the use of bumetanide continuous infusions in critically ill pediatric patients. DESIGN: This study was an institutional review board approved, single-center, retrospective chart review of 95 patients. Dosing practices were described by rate (μg/kg/hr), duration (days), and previous diuretic use. Efficacy, determined by ability to achieve negative fluid balance and time to reach negative fluid balance, was assessed at 12, 24, and 48 hours. Safety was evaluated based on prevalence of adverse drug reactions. Adverse drug reactions were predefined as serum potassium concentration less than 3 mEq/L, serum chloride concentration less than 90 mEq/L, serum carbon dioxide concentration greater than 35 mEq/L, and serum creatinine increased greater than 1.5 times baseline and above patient-specific normal range. SETTING: Le Bonheur Children's Hospital, Memphis, TN. PATIENTS: Critically ill patients who are 18 years old or younger and received bumetanide continuous infusions. A total of 95 patients were included. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The mean dose of bumetanide was 5.7 ± 2.2 μg/kg/hr (1-10 μg/kg/hr) with a median duration of 3.3 days (0.3-18.5). The total percentage of patients achieving negative fluid balance by 48 hours was 76{\%} with 54{\%} of patients reaching negative fluid balance within 12 hours. CONCLUSIONS: This study showed that a bumetanide dose of 5.7 μg/kg/hr was effective in achieving negative fluid balance in the majority of critically ill pediatric patients. Additionally, bumetanide appears to be a safe loop diuretic for use as a continuous infusion at the doses described in critically ill pediatric patients.",
author = "McCallister, {Katie M.} and Chhim, {Rebecca F.} and Mario Briceno-Medina and Chasity Shelton and Mayte Figueroa and Mark Rayburn",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/PCC.0000000000000303",
language = "English (US)",
volume = "16",
pages = "e19--e22",
journal = "Pediatric Critical Care Medicine",
issn = "1529-7535",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Bumetanide continuous infusions in critically ill pediatric patients

AU - McCallister, Katie M.

AU - Chhim, Rebecca F.

AU - Briceno-Medina, Mario

AU - Shelton, Chasity

AU - Figueroa, Mayte

AU - Rayburn, Mark

PY - 2015/1/1

Y1 - 2015/1/1

N2 - OBJECTIVE: Limited data exist for the use of bumetanide continuous infusions in children. The purpose of this study was to evaluate the use of bumetanide continuous infusions in critically ill pediatric patients. DESIGN: This study was an institutional review board approved, single-center, retrospective chart review of 95 patients. Dosing practices were described by rate (μg/kg/hr), duration (days), and previous diuretic use. Efficacy, determined by ability to achieve negative fluid balance and time to reach negative fluid balance, was assessed at 12, 24, and 48 hours. Safety was evaluated based on prevalence of adverse drug reactions. Adverse drug reactions were predefined as serum potassium concentration less than 3 mEq/L, serum chloride concentration less than 90 mEq/L, serum carbon dioxide concentration greater than 35 mEq/L, and serum creatinine increased greater than 1.5 times baseline and above patient-specific normal range. SETTING: Le Bonheur Children's Hospital, Memphis, TN. PATIENTS: Critically ill patients who are 18 years old or younger and received bumetanide continuous infusions. A total of 95 patients were included. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The mean dose of bumetanide was 5.7 ± 2.2 μg/kg/hr (1-10 μg/kg/hr) with a median duration of 3.3 days (0.3-18.5). The total percentage of patients achieving negative fluid balance by 48 hours was 76% with 54% of patients reaching negative fluid balance within 12 hours. CONCLUSIONS: This study showed that a bumetanide dose of 5.7 μg/kg/hr was effective in achieving negative fluid balance in the majority of critically ill pediatric patients. Additionally, bumetanide appears to be a safe loop diuretic for use as a continuous infusion at the doses described in critically ill pediatric patients.

AB - OBJECTIVE: Limited data exist for the use of bumetanide continuous infusions in children. The purpose of this study was to evaluate the use of bumetanide continuous infusions in critically ill pediatric patients. DESIGN: This study was an institutional review board approved, single-center, retrospective chart review of 95 patients. Dosing practices were described by rate (μg/kg/hr), duration (days), and previous diuretic use. Efficacy, determined by ability to achieve negative fluid balance and time to reach negative fluid balance, was assessed at 12, 24, and 48 hours. Safety was evaluated based on prevalence of adverse drug reactions. Adverse drug reactions were predefined as serum potassium concentration less than 3 mEq/L, serum chloride concentration less than 90 mEq/L, serum carbon dioxide concentration greater than 35 mEq/L, and serum creatinine increased greater than 1.5 times baseline and above patient-specific normal range. SETTING: Le Bonheur Children's Hospital, Memphis, TN. PATIENTS: Critically ill patients who are 18 years old or younger and received bumetanide continuous infusions. A total of 95 patients were included. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The mean dose of bumetanide was 5.7 ± 2.2 μg/kg/hr (1-10 μg/kg/hr) with a median duration of 3.3 days (0.3-18.5). The total percentage of patients achieving negative fluid balance by 48 hours was 76% with 54% of patients reaching negative fluid balance within 12 hours. CONCLUSIONS: This study showed that a bumetanide dose of 5.7 μg/kg/hr was effective in achieving negative fluid balance in the majority of critically ill pediatric patients. Additionally, bumetanide appears to be a safe loop diuretic for use as a continuous infusion at the doses described in critically ill pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=84923205971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923205971&partnerID=8YFLogxK

U2 - 10.1097/PCC.0000000000000303

DO - 10.1097/PCC.0000000000000303

M3 - Article

C2 - 25560424

AN - SCOPUS:84923205971

VL - 16

SP - e19-e22

JO - Pediatric Critical Care Medicine

JF - Pediatric Critical Care Medicine

SN - 1529-7535

IS - 2

ER -